Skip to main content
Signal8

Tarsus Pharmaceuticals, Inc. (TARS)

Sector: Biological Products, (No Diagnostic Substances)

Industry: Biotechnology

Tarsus Pharmaceuticals, Inc. logo

Tarsus Pharmaceuticals, Inc.

NASDAQ:TARSHealthcare
+1.60%$68.60
CLOSED
AH$70.00+2.04%vs close
Mkt Cap$3.38B
Float37.55M
O/S49.31M
VOL1.09M sh
$ Vol$74.46M
RVOL0.99×
Inst Own95.2%
SI15.3%
Dilution
Tarsus Pharmaceuticals, Inc. logoNASDAQ:TARSClosed$68.60+1.60%
Historical Data
DateOpenHighLowCloseVolume
Nov 6, 202667.7869.0366.5368.601,090,209
Nov 5, 202669.4070.9466.8467.521,716,287
Nov 4, 202674.0174.6365.3469.072,550,743
Nov 3, 202674.3075.3670.3972.64755,780
Nov 2, 202674.8876.0972.3973.32428,693
Oct 30, 202674.9976.2774.3074.85595,209
Oct 29, 202672.9074.7672.7474.20458,416
Oct 28, 202669.6172.4469.5072.05400,071
Oct 27, 202669.7871.7169.1470.76747,960
Oct 26, 202668.3771.6268.3670.03877,126
Oct 23, 202671.4871.7067.6568.20556,620
Oct 22, 202670.9373.1169.5572.08688,656
Oct 21, 202670.8572.8170.2070.50945,911
Oct 20, 202669.5472.4667.9371.03898,979
Oct 19, 202668.0870.9468.0869.50682,552
Oct 16, 202670.8770.8767.9568.072,871,594
Oct 15, 202672.5874.9470.5570.991,398,351
Oct 14, 202670.5773.3570.0372.291,166,768
Oct 13, 202674.5075.0270.3270.821,632,816
Oct 12, 202673.2076.6472.9774.401,463,048
Analyst Coverage
Analyst Coverage
ConsensusBuy
Price Target (median, last 90d)
$107.50+56.7%
Low $100High $116
Ratings Distribution
BUY
9
HOLD
1
SELL
0
TOTAL10
Insider Trades
InsiderTypeShares
Clase Neera profile photoClase NeeraGrant/Award6.7K
Clase Neera profile photoClase NeeraGrant/Award10.6K
LINK WILLIAM J PHD profile photoLINK WILLIAM J PHDOption Exercise201
PYOTT DAVID E I profile photoPYOTT DAVID E IOption Exercise201
LINK WILLIAM J PHD profile photoLINK WILLIAM J PHDSale759
PYOTT DAVID E I profile photoPYOTT DAVID E IOption Exercise201
Shareholders
95.2%
Institutional
(257)
1.0%
Insiderⓘ
(15)
10.7%
5%+ Owners
(2)
-
Unattributed (incl. retail)ⓘ
Institutional95.2%
Insider1.0%
5%+ Beneficial10.7%
Sources: 13F, Form 4, 13D/13GO/S: 49.3M · as of 29 Oct 2026 · SEC cover page
Insiders & Institutional Holders

Insiders

Top institutional holders

About

Tarsus Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm dedicated to advancing and commercializing innovative therapies, primarily focusing on ocular conditions.

Its leading investigational drug, TP-03, a novel treatment currently in Phase III trials, is being developed to address blepharitis specifically caused by Demodex mite infestations, as well as meibomian gland disease. Beyond this, Tarsus is also progressing TP-04 for rosacea and TP-05, which targets Lyme disease prevention and aims to reduce community-level malaria. A core element of its development strategy involves lotilaner, a compound utilized to tackle a variety of human diseases across diverse therapeutic areas, encompassing eye care, dermatology, and other medical fields. Established in 2016, the company maintains its headquarters in Irvine, California.

Key Metrics
Market Cap$3.38B
Enterprise Value--
P/E Ratio--
Est. Net Cash/Share--
Institutional Ownership95.20%

based on 49.31M shares outstanding

SectorHealthcare
IndustryBiotechnology
ExchangeNASDAQ
CountryUSUS
IPO DateOct 16, 2020
Shares Outstanding49.31M
Authorized Shares
Float37.55M
52-Week Range
$53.89$91.53
$68.60(39th percentile)
Volume
Average Daily Volume1.10M
1.09M today vs 1.10M avg(-1%)

30d Avg

1.10M

60d Avg

911.07K

90d Avg

869.78K

Earnings
Dividend History
No dividend history available
Compliance Status
Loading compliance data...